Clinical Trials

Veliparib (ABT-888) has been extensively evaluated across Phase 1, Phase 2, and Phase 3 clinical trials sponsored by major organizations, including the National Cancer Institute and AbbVie. These numerous investigations target a broad spectrum of oncological indications, such as BRCA-mutated and triple-negative breast cancer, ovarian cancer, acute myeloid leukemia, glioblastoma, and solid tumors. While many of these trials are completed, others exhibit active, terminated, or withdrawn recruitment statuses.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01042379 RECRUITING
Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer
QuantumLeap Healthcare Collaborative
 2010-03-01 PHASE2
NCT02595905 COMPLETED
Metastatic BRCA Hereditary Breast Carcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Neoplasm in the Brain; Metastatic Triple-Negative Breast Carcinoma; Recurrent Breast Carcinoma; Stage IV Breast Cancer AJCC v6 and v7
National Cancer Institute (NCI)
 2016-09-15 PHASE2
NCT01585805 ACTIVE_NOT_RECRUITING
Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
National Cancer Institute (NCI)
 2012-05-15 PHASE2
NCT01251874 ACTIVE_NOT_RECRUITING
Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
 2010-11-22 PHASE1
NCT01149083 COMPLETED
Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Unresectable Breast Carcinoma
National Cancer Institute (NCI)
 2010-06-30 PHASE2
NCT01618357 COMPLETED
Breast Cancer
Richard Zellars
 2013-07-22 PHASE1
NCT03289910 ACTIVE_NOT_RECRUITING
Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Atypical Chronic Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Essential Thrombocythemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Polycythemia Vera; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2018-09-24 PHASE2
NCT03581292 ACTIVE_NOT_RECRUITING
Anaplastic Astrocytoma; Glioblastoma; Malignant Glioma
National Cancer Institute (NCI)
 2018-11-06 PHASE2
NCT01434316 ACTIVE_NOT_RECRUITING
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
 2011-11-11 PHASE1
NCT02152982 ACTIVE_NOT_RECRUITING
Glioblastoma; Gliosarcoma
National Cancer Institute (NCI)
 2014-12-15 PHASE2; PHASE3
NCT03400306 WITHDRAWN
Cancer - Ovarian
AbbVie
 2021-11-15 PHASE1
NCT00740805 ACTIVE_NOT_RECRUITING
Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Solid Neoplasm
National Cancer Institute (NCI)
 2008-08-18 PHASE1
NCT02158507 COMPLETED
Metastatic Triple Negative Breast Cancer
University of Alabama at Birmingham
 2014-09-04
NCT01827384 COMPLETED
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
 2014-01-07 PHASE2
NCT03227016 UNKNOWN
Small Cell Lung Cancer SCLC
Central European Society for Anticancer Drug Research
 2016-10 PHASE1
NCT02723864 COMPLETED
Neoplasms
National Cancer Institute (NCI)
 2017-08-09 PHASE1
NCT02860819 COMPLETED
Testicular Cancer
National Cancer Institute, Slovakia
 2016-08-01 PHASE2
NCT03044795 WITHDRAWN
Cancer
University Medical Center Groningen
 2019-11 PHASE2
NCT02921256 COMPLETED
Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v7; Stage III Rectal Cancer AJCC v7
National Cancer Institute (NCI)
 2017-01-11 PHASE2
NCT00576654 COMPLETED
Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Triple-Negative Breast Carcinoma; Unresectable Solid Neoplasm
National Cancer Institute (NCI)
 2008-03-18 PHASE1
NCT02631733 COMPLETED
Malignant Solid Neoplasm
National Cancer Institute (NCI)
 2017-05-31 PHASE1
NCT02264990 COMPLETED
Non-squamous Non-small Cell Lung Cancer
AbbVie
 2014-09-30 PHASE3
NCT03044795 Withdrawn
Cancer
University Medical Center Groningen|AbbVie|Dutch Cancer Society
 2019-11 Phase 2
NCT01576172 COMPLETED
Castration-Resistant Prostate Carcinoma; Recurrent Prostate Carcinoma; Stage IV Prostate Cancer AJCC v7
National Cancer Institute (NCI)
 2012-03-30 PHASE2
NCT02944396 COMPLETED
Non-Small Cell Lung Cancer
AbbVie
 2016-12-23 PHASE1
NCT02412371 TERMINATED
Non-small Cell Lung Cancer Stage III
AbbVie
 2015-04-30 PHASE1; PHASE2
NCT01386385 ACTIVE_NOT_RECRUITING
Lung Adenocarcinoma; Lung Adenocarcinoma, Mixed Subtype; Lung Large Cell Carcinoma; Lung Squamous Cell Carcinoma; Minimally Invasive Lung Adenocarcinoma; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Non-Small Cell Cancer AJCC v7
National Cancer Institute (NCI)
 2011-06-20 PHASE1; PHASE2
NCT02470585 TERMINATED
Ovarian Cancer; Ovarian Neoplasm
AbbVie
 2015-07-14 PHASE3
NCT02890355 COMPLETED
Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v6 and v7
National Cancer Institute (NCI)
 2016-10-27 PHASE2
NCT02289690 COMPLETED
Small Cell Lung Cancer
AbbVie
 2014-10-13 PHASE1; PHASE2
NCT02163694 COMPLETED
Metastatic Breast Cancer
AbbVie
 2014-04-08 PHASE3
NCT03032614 WITHDRAWN
Breast Cancer Stage IV; Ovarian Cancer; BRCA1 Mutation; BRCA2 Mutation
The University of Texas Health Science Center at San Antonio
 2017-09-30 PHASE2
NCT02831179 WITHDRAWN
Functional Pancreatic Neuroendocrine Tumor; Malignant Somatostatinoma; Merkel Cell Carcinoma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Carcinoid Tumor; Multiple Endocrine Neoplasia Type 1; Multiple Endocrine Neoplasia Type 2A; Multiple Endocrine Neoplasia Type 2B; Neuroendocrine Neoplasm; Non-Functional Pancreatic Neuroendocrine Tumor; Pancreatic Glucagonoma; Pancreatic Insulinoma; Recurrent Adrenal Cortex Carcinoma; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Merkel Cell Carcinoma; Somatostatin-Producing Neuroendocrine Tumor; Stage III Adrenal Cortex Carcinoma; Stage III Thyroid Gland Medullary Carcinoma; Stage IIIA Merkel Cell Carcinoma; Stage IIIB Merkel Cell Carcinoma; Stage IV Adrenal Cortex Carcinoma; Stage IV Merkel Cell Carcinoma; Stage IVA Thyroid Gland Medullary Carcinoma; Stage IVB Thyroid Gland Medullary Carcinoma; Stage IVC Thyroid Gland Medullary Carcinoma; Thymic Carcinoid Tumor; VIP-Producing Neuroendocrine Tumor; Well Differentiated Adrenal Cortex Carcinoma; Zollinger Ellison Syndrome
Vanderbilt-Ingram Cancer Center
 2017-12 PHASE1
NCT01012817 ACTIVE_NOT_RECRUITING
Metastatic Malignant Solid Neoplasm; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable Solid Neoplasm
National Cancer Institute (NCI)
 2009-11-03 PHASE1; PHASE2
NCT01489865 COMPLETED
Metastatic Pancreatic Cancer
Georgetown University
 2011-01-03 PHASE1; PHASE2
NCT01506609 COMPLETED
Metastatic Breast Cancer
AbbVie
 2012-01-23 PHASE2
NCT01514201 COMPLETED
Anaplastic Astrocytoma; Brain Stem Glioma; Childhood Mixed Glioma; Fibrillary Astrocytoma; Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma; Untreated Childhood Anaplastic Astrocytoma; Untreated Childhood Brain Stem Glioma; Untreated Childhood Fibrillary Astrocytoma; Untreated Childhood Giant Cell Glioblastoma; Untreated Childhood Glioblastoma; Untreated Childhood Gliosarcoma
National Cancer Institute (NCI)
 2012-02-01 PHASE1; PHASE2
NCT03061188 COMPLETED
Advanced Solid Neoplasm; Aggressive Non-Hodgkin Lymphoma; Recurrent Solid Neoplasm; Refractory Mantle Cell Lymphoma; T-Cell Non-Hodgkin Lymphoma; Unresectable Solid Neoplasm
Northwestern University
 2017-05-23 PHASE1
NCT01711541 COMPLETED
Head and Neck Squamous Cell Carcinoma; Stage IVA Oropharyngeal Carcinoma AJCC v7; Stage IVB Oropharyngeal Carcinoma AJCC v7
National Cancer Institute (NCI)
 2012-10-22 PHASE1; PHASE2
NCT01540565 COMPLETED
BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ovarian Epithelial Tumor; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
National Cancer Institute (NCI)
 2012-04-09 PHASE2
NCT01366144 ACTIVE_NOT_RECRUITING
Breast Carcinoma; Carcinoma of Unknown Primary; Endometrial Carcinoma; Esophageal Carcinoma; Liver Failure; Lung Carcinoma; Malignant Head and Neck Neoplasm; Malignant Testicular Neoplasm; Melanoma; Metastatic Malignant Solid Neoplasm; Ovarian Carcinoma; Renal Failure; Unresectable Malignant Neoplasm; Urothelial Carcinoma
National Cancer Institute (NCI)
 2011-06-20 PHASE1
NCT01749397 COMPLETED
Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7
National Cancer Institute (NCI)
 2012-12-07 PHASE1
NCT02305758 COMPLETED
Untreated Metastatic Colorectal Cancer
AbbVie
 2014-12-02 PHASE2
NCT02723864 Completed
Neoplasms
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
 2017-08-09 Phase 1
NCT01908478 COMPLETED
Pancreatic Cancer
Cedars-Sinai Medical Center
 2013-10-02 PHASE1
NCT01145430 COMPLETED
Estrogen Receptor Negative; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
 2010-06-01 PHASE1
NCT00892736 COMPLETED
Basal-Like Breast Carcinoma; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Breast Carcinoma; Estrogen Receptor Negative; HER2/Neu Negative; Hereditary Breast and Ovarian Cancer Syndrome; Ovarian Carcinoma; Pancreatic Carcinoma; Progesterone Receptor Negative; Prostate Carcinoma; Recurrent Breast Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Solid Neoplasm; Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
 2009-04-20 PHASE1
NCT01853306 COMPLETED
Oncology; BRCA Mutated; High Grade Serous Ovarian Cancer; BRCA Mutated Breast Cancer
AbbVie
 2013-03-18 PHASE1
NCT01281852 COMPLETED
Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Recurrent Cervical Carcinoma; Stage IVB Cervical Cancer AJCC v6 and v7
National Cancer Institute (NCI)
 2011-03-14 PHASE1
NCT01638546 ACTIVE_NOT_RECRUITING
Recurrent Lung Small Cell Carcinoma
National Cancer Institute (NCI)
 2012-07-27 PHASE2
NCT02106546 COMPLETED
Squamous Non-Small Cell Lung Cancer
AbbVie
 2014-04-10 PHASE3
NCT01642251 COMPLETED
Extensive Stage Small Cell Lung Carcinoma; Large Cell Lung Carcinoma; Neuroendocrine Carcinoma; Small Cell Carcinoma; Stage IV Non-Small Cell Lung Cancer AJCC v7
National Cancer Institute (NCI)
 2012-09-28 PHASE1; PHASE2
NCT01351909 ACTIVE_NOT_RECRUITING
Locally Advanced Unresectable Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
National Cancer Institute (NCI)
 2011-05-02 PHASE1
NCT01264432 COMPLETED
Adult Solid Neoplasm; Peritoneal Carcinomatosis; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
National Cancer Institute (NCI)
 2011-01-01 PHASE1
NCT00588991 COMPLETED
Adult Acute Megakaryoblastic Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With Maturation; Adult Acute Myeloid Leukemia With Minimal Differentiation; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A; Adult Acute Myeloid Leukemia Without Maturation; Adult Acute Myelomonocytic Leukemia; Adult Erythroleukemia; Adult Pure Erythroid Leukemia; Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive; Chronic Myelomonocytic Leukemia; De Novo Myelodysplastic Syndrome; Essential Thrombocythemia; Hematopoietic and Lymphoid Cell Neoplasm; Myelodysplastic Syndrome; Polycythemia Vera; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome
National Cancer Institute (NCI)
 2008-02-04 PHASE1
NCT00989651 COMPLETED
Fallopian Tube Carcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Neoplasm; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Ovarian Brenner Tumor; Ovarian Carcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Tumor; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Stage IIA Fallopian Tube Cancer AJCC v6 and v7; Stage IIA Ovarian Cancer AJCC V6 and v7; Stage IIB Fallopian Tube Cancer AJCC v6 and v7; Stage IIB Ovarian Cancer AJCC v6 and v7; Stage IIC Fallopian Tube Cancer AJCC v6 and v7; Stage IIC Ovarian Cancer AJCC v6 and v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Ovarian Cancer AJCC v6 and v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Ovarian Cancer AJCC v6 and v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Ovarian Cancer AJCC v6 and v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Ovarian Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7
National Cancer Institute (NCI)
 2009-10-28 PHASE1
NCT02033551 COMPLETED
Breast Cancer; Ovarian Cancer; Colon Cancer; Lung Cancer; Gastric Cancer; Solid Tumors
AbbVie
 2013-12 PHASE1
NCT01063816 COMPLETED
Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)
 2010-01 PHASE1
NCT01459380 COMPLETED
Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Cystadenocarcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Undifferentiated Ovarian Carcinoma
National Cancer Institute (NCI)
 2011-10-11 PHASE1
NCT01017640 COMPLETED
Solid Neoplasm
National Cancer Institute (NCI)
 2009-10 PHASE1
NCT02032277 COMPLETED
Triple Negative Breast Cancer
AbbVie
 2014-04-02 PHASE3
NCT02483104 COMPLETED
Ovarian Cancer
AbbVie
 2015-07 PHASE1
NCT01266447 COMPLETED
Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Small Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Carcinoma; Stage III Cervical Cancer; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer
National Cancer Institute (NCI)
 2011-02 PHASE2
NCT01472783 COMPLETED
Recurrent, Epithelial Ovarian Cancer
Vejle Hospital
 2011-11 PHASE1; PHASE2
NCT02210663 COMPLETED
Advanced Solid Tumors
AbbVie
 2014-07 PHASE1
NCT00804908 COMPLETED
Melanoma; Metastatic Melanoma; Skin Cancer
AbbVie (prior sponsor, Abbott)
 2009-02 PHASE2
NCT02483104 Completed
Ovarian Cancer
AbbVie
 2015-07 Phase 1
NCT01281150 COMPLETED
Adult Solid Neoplasm; Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; Male Breast Carcinoma; Progesterone Receptor Negative; Recurrent Breast Carcinoma; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Triple-Negative Breast Carcinoma
National Cancer Institute (NCI)
 2011-01 PHASE1
NCT01326702 COMPLETED
Adult B Acute Lymphoblastic Leukemia; Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Adult Solid Neoplasm; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Chronic Lymphocytic Leukemia; Cutaneous B-Cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Hepatosplenic T-Cell Lymphoma; Intraocular Lymphoma; Lymphomatous Involvement of Non-Cutaneous Extranodal Site; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Nodal Marginal Zone Lymphoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides and Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Plasma Cell Myeloma; Small Intestinal Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
National Cancer Institute (NCI)
 2011-07 PHASE1; PHASE2
NCT01818063 COMPLETED
Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
 2013-04-25 PHASE2
NCT01104259 COMPLETED
Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Hereditary Breast/Ovarian Cancer - BRCA1; Hereditary Breast/Ovarian Cancer - BRCA2; Male Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
University of Washington
 2010-07 PHASE1
NCT01495351 COMPLETED
Multiple Myeloma
AHS Cancer Control Alberta
 2011-10 PHASE1
NCT01657799 COMPLETED
Brain Metastases From Non-small Cell Lung Cancer
AbbVie (prior sponsor, Abbott)
 2012-10-19 PHASE2
NCT01589419 COMPLETED
Locally Advanced Rectal Cancer
AbbVie (prior sponsor, Abbott)
 2012-06 PHASE1
NCT01690598 COMPLETED
Ovarian Cancer
Vejle Hospital
 2012-11 PHASE1; PHASE2
NCT01123876 COMPLETED
Gastric Cancer
AbbVie (prior sponsor, Abbott)
 2010-03 PHASE1
NCT01306032 COMPLETED
Ovarian Cancer; Primary Peritoneal Cancer; Serous Carcinoma Cancer; Triple-Negative Breast Cancer; Fallopian Tube Cancer
National Cancer Institute (NCI)
 2011-01-12 PHASE2
NCT02009631 COMPLETED
Breast Cancer; Ovarian Cancer; Colon Cancer; Lung Cancer; Gastric Cancer; Solid Tumors
AbbVie
 2013-11 PHASE1
NCT01477489 COMPLETED
Breast Cancer
University of Michigan Rogel Cancer Center
 2012-01 PHASE1
NCT01205828 TERMINATED
Hepatocellular Carcinoma
Georgetown University
 2010-08 PHASE2
NCT01560104 COMPLETED
Non-Small -Cell Lung Cancer
AbbVie (prior sponsor, Abbott)
 2012-02 PHASE2
NCT01026493 COMPLETED
Brain and Central Nervous System Tumors
Radiation Therapy Oncology Group
 2010-07 PHASE1; PHASE2
NCT01139970 COMPLETED
Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A; Adult Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA; Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Adult T Acute Lymphoblastic Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
 2010-06-04 PHASE1
NCT01154426 COMPLETED
Adult Solid Neoplasm; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier
National Cancer Institute (NCI)
 2010-05 PHASE1
NCT01233505 TERMINATED
Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Ovarian Mucinous Cystadenocarcinoma; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer; Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI)
 2010-10 PHASE1
NCT01617928 COMPLETED
Solid Tumors
AbbVie (prior sponsor, Abbott)
 2012-05 PHASE1
NCT01051596 COMPLETED
Colorectal Cancer
Georgetown University
 2009-09 PHASE2
NCT01113957 COMPLETED
Ovarian Cancer
AbbVie (prior sponsor, Abbott)
 2010-03 PHASE2
NCT00649207 COMPLETED
Brain Diseases; Brain Neoplasms; Central Nervous System Diseases; Neoplasm Metastasis; Nervous System Neoplasms
AbbVie (prior sponsor, Abbott)
 2008-03 PHASE1
NCT01282333 TERMINATED
Advanced Adult Primary Liver Cancer; Localized Unresectable Adult Primary Liver Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Stage III Bladder Cancer; Stage III Pancreatic Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IV Bladder Cancer; Stage IV Non-small Cell Lung Cancer; Stage IV Pancreatic Cancer; Transitional Cell Carcinoma of the Bladder; Unresectable Extrahepatic Bile Duct Cancer; Unresectable Gallbladder Cancer
National Cancer Institute (NCI)
 2011-01 PHASE1
NCT00535119 COMPLETED
Adult Solid Neoplasm; BRCA1 Mutation Carrier; BRCA2 Mutation Carrier; Hereditary Breast and Ovarian Cancer Syndrome
National Cancer Institute (NCI)
 2007-09 PHASE1
NCT01009788 COMPLETED
Breast Cancer; Metastatic Breast Cancer; BRCA1 Gene Mutation; brca2 Gene Mutation
Steven J Isakoff, MD, PhD
 2009-11 PHASE2
NCT01445522 COMPLETED
Neoplasms; Lymphoma
National Cancer Institute (NCI)
 2008-12-03 PHASE1
NCT00770471 COMPLETED
Brain and Central Nervous System Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2009-07-13 PHASE1
NCT01419548 WITHDRAWN
Neoplasms
National Cancer Institute (NCI)
 2011-07-29 PHASE1
NCT01193140 COMPLETED
Solid Tumor Cancers
Abbott
 2010-07 PHASE2
NCT00946335 COMPLETED
Childhood Atypical Teratoid/Rhabdoid Tumor; Childhood Central Nervous System Germ Cell Tumor; Childhood Choroid Plexus Tumor; Childhood Craniopharyngioma; Childhood Ependymoblastoma; Childhood Grade I Meningioma; Childhood Grade II Meningioma; Childhood Grade III Meningioma; Childhood High-grade Cerebellar Astrocytoma; Childhood High-grade Cerebral Astrocytoma; Childhood Infratentorial Ependymoma; Childhood Low-grade Cerebellar Astrocytoma; Childhood Low-grade Cerebral Astrocytoma; Childhood Medulloepithelioma; Childhood Mixed Glioma; Childhood Oligodendroglioma; Childhood Supratentorial Ependymoma; Recurrent Childhood Brain Stem Glioma; Recurrent Childhood Brain Tumor; Recurrent Childhood Cerebellar Astrocytoma; Recurrent Childhood Cerebral Astrocytoma; Recurrent Childhood Ependymoma; Recurrent Childhood Medulloblastoma; Recurrent Childhood Pineoblastoma; Recurrent Childhood Spinal Cord Neoplasm; Recurrent Childhood Subependymal Giant Cell Astrocytoma; Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor; Recurrent Childhood Visual Pathway and Hypothalamic Glioma
National Cancer Institute (NCI)
 2009-07 PHASE1
NCT01085422 COMPLETED
Prostate Cancer
AbbVie (prior sponsor, Abbott)
 2010-04 PHASE1
NCT01199224 COMPLETED
Solid Tumors
AbbVie
 2010-06 PHASE1
NCT00526617 COMPLETED
Non-hematologic Malignancies; Metastatic Melanoma; Breast Cancer; Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer; Hepatocellular Carcinoma
AbbVie
 2007-08 PHASE1
NCT00553189 COMPLETED
Solid Tumors; Lymphomas
National Cancer Institute (NCI)
 2007-08-09 PHASE1
NCT00387608 COMPLETED
Leukemia; Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC)
 2006-06 PHASE1
NCT00994071 COMPLETED
Medulloblastoma; Pontine Glioma; Ependymoma; Astrocytoma; PNET
National Cancer Institute (NCI)
 2009-09-22 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-05-06)

Check the Veliparib (ABT-888) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Veliparib (ABT-888) selectively inhibits poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 with Ki values of 5.2 nM and 2.9 nM, respectively, thereby preventing DNA single-strand break repair and driving the accumulation of lethal double-strand breaks. This disruption of cellular DNA repair mechanisms triggers increased autophagy and apoptosis, ultimately enhancing therapeutic sensitivity in clinical targets such as BRCA-mutated breast carcinoma, ovarian cancer, and solid neoplasms.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.